AtriCure (ATRC) Projected to Post Earnings on Tuesday

AtriCure (NASDAQ:ATRC - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Tuesday, April 29th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $122.92 million for the quarter.

AtriCure Stock Performance

Shares of NASDAQ:ATRC traded down $0.35 during mid-day trading on Friday, reaching $33.40. The company had a trading volume of 426,193 shares, compared to its average volume of 655,652. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The company's 50-day moving average price is $34.32 and its 200-day moving average price is $34.60. AtriCure has a one year low of $18.94 and a one year high of $43.11. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -35.16 and a beta of 1.65.

Insider Activity

In related news, Director Karen Prange sold 6,100 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the transaction, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.50% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on ATRC shares. JMP Securities reiterated a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a research note on Monday, February 10th. BTIG Research reiterated a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. JPMorgan Chase & Co. lowered their price target on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, March 27th. Piper Sandler lifted their price objective on shares of AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group lowered their target price on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.44.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.